Health Care·Pharmaceuticals·$49.1B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.65 | N/A | +0.34% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $0.65 | N/A | +0.34% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Overall, management conveyed a positive outlook on earnings performance. However, they did not provide specific guidance for future quarters.
Management expressed satisfaction with the EPS performance despite not providing revenue figures.
They highlighted ongoing strength in their product portfolio.
Zoetis Inc's earnings report showed a positive surprise in EPS, which likely contributed to the stock's 4.34% increase. The lack of revenue data leaves some uncertainty, but management's positive tone suggests confidence in their ongoing operations. Investors may view the EPS beat as a sign of strong performance in a competitive market.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
ROPER TECHNOLOGIES I
Oct 30, 2017